<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794477</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1802-II-202</org_study_id>
    <nct_id>NCT05794477</nct_id>
  </id_info>
  <brief_title>An Open Label, Multicenter, Phase Ib/II Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors</brief_title>
  <official_title>An Open Label, Multicenter, Phase Ib/II Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Hengrui Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Hengrui Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to observe and evaluate the tolerability, safety, pharmacokinetics&#xD;
      and immunogenicity of SHR-1802 combined with adebrelimab in patients with advanced solid&#xD;
      tumors, determine the RP2D of SHR-1802 combined with adebrelimab ± chemotherapy, and evaluate&#xD;
      the efficacy of SHR-1802 combined with adebrelimab ± chemotherapy in patients with advanced&#xD;
      solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 28, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dose-exploration：Six patients will be enrolled for tolerability observation. If ≥2 subjects in the previous dose level experienced DLTS, an additional 6 subjects in the other dose level were enrolled.&#xD;
Efficacy-expansion: After determination of the recommended dose for Phase II (RP2D), selected cohorts with different tumor types will be expanded.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase II dose (RP2D)</measure>
    <time_frame>up to 2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Objective Response Rate, determined according to RECIST v1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Duration of Response, determined according to RECIST v1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Disease Control Rate, determined according to RECIST v1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS assessed by investigator</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Progression Free Survival, determined according to RECIST v1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Time to Response，determined according to RECIST v1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (overall survival)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>From date of treatment start to any cause death or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month OS rate</measure>
    <time_frame>from the date of the first dose up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>phase Ib：SHR-1802+Adebrelimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>phase II cohort 1: SHR-1802+Adebrelimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>phase II cohort 2: SHR-1802+Adebrelimab + Platinum Doublet Chemotherapy (PDCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>phase II cohort 3: SHR-1802+Adebrelimab + PDCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>phase II cohort 4: SHR-1802+Adebrelimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adebrelimab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>phase II cohort 1: SHR-1802+Adebrelimab</arm_group_label>
    <arm_group_label>phase II cohort 2: SHR-1802+Adebrelimab + Platinum Doublet Chemotherapy (PDCT)</arm_group_label>
    <arm_group_label>phase II cohort 3: SHR-1802+Adebrelimab + PDCT</arm_group_label>
    <arm_group_label>phase II cohort 4: SHR-1802+Adebrelimab</arm_group_label>
    <arm_group_label>phase Ib：SHR-1802+Adebrelimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SHR-1802</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>phase II cohort 1: SHR-1802+Adebrelimab</arm_group_label>
    <arm_group_label>phase II cohort 2: SHR-1802+Adebrelimab + Platinum Doublet Chemotherapy (PDCT)</arm_group_label>
    <arm_group_label>phase II cohort 3: SHR-1802+Adebrelimab + PDCT</arm_group_label>
    <arm_group_label>phase II cohort 4: SHR-1802+Adebrelimab</arm_group_label>
    <arm_group_label>phase Ib：SHR-1802+Adebrelimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin/Cisplatin</intervention_name>
    <description>Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.</description>
    <arm_group_label>phase II cohort 2: SHR-1802+Adebrelimab + Platinum Doublet Chemotherapy (PDCT)</arm_group_label>
    <arm_group_label>phase II cohort 3: SHR-1802+Adebrelimab + PDCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel/Nab-Paclitaxel/Pemetrexed</intervention_name>
    <description>Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.</description>
    <arm_group_label>phase II cohort 2: SHR-1802+Adebrelimab + Platinum Doublet Chemotherapy (PDCT)</arm_group_label>
    <arm_group_label>phase II cohort 3: SHR-1802+Adebrelimab + PDCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide a written informed consent；&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;&#xD;
&#xD;
          3. Has a life expectancy≥ 12 weeks；&#xD;
&#xD;
          4. At least one measurable lesion according to RECIST v1.1；&#xD;
&#xD;
          5. Pathologically confirmed advanced solid tumor；&#xD;
&#xD;
          6. Adequate bone marrow reserve and organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have received anti-PD-1 or PD-L1 antibody therapy;&#xD;
&#xD;
          2. Subjects with other malignant tumors in the past 3 years;&#xD;
&#xD;
          3. Have uncontrolled clinically symptomatic pleural effusion, pericardial effusion, or&#xD;
             ascites;&#xD;
&#xD;
          4. Previous or current interstitial pneumonia/interstitial lung disease ;&#xD;
&#xD;
          5. History of autoimmune disease with the possibility of recurrence or active autoimmune&#xD;
             disease;&#xD;
&#xD;
          6. Severe infection within 1 month before the first study drug administration;&#xD;
&#xD;
          7. The presence of other serious physical or mental disorders or abnormalities in&#xD;
             laboratory tests that may increase the risk of study participation or interfere with&#xD;
             study results, as well as patients deemed unsuitable for study participation by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shuni Wang, M.M</last_name>
    <phone>+86 15921207253</phone>
    <email>shuni.wang@hengrui.com</email>
  </overall_contact>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

